Takeda Pharmaceutical (NYSE:TAK) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Takeda Pharmaceutical from “buy” to “hold.” Despite the downgrade, MarketBeat’s analyst consensus remains “Buy,” with one Strong Buy, two Buy, and one Hold rating.
• Takeda shares opened at $21.43, near their 12-month high of $21.73; the company’s market capitalization was about $68.7 billion.
• Company insiders sold a combined 238,974 shares, worth approximately $4.55 million, over the past 90 days.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities analysts have also issued reports on the company. Zacks Research upgraded Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 30th. Weiss Ratings upgraded Takeda Pharmaceutical from a "hold (c)" rating to a "hold (c+)" rating in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy".

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $21.43 on Friday. The business has a 50 day moving average price of $19.40 and a 200 day moving average price of $17.78. The company has a market cap of $68.68 billion, a price-to-earnings ratio of 12.07 and a beta of -0.02. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56. Takeda Pharmaceutical has a twelve month low of $13.91 and a twelve month high of $21.73.

Insider Buying and Selling

In other Takeda Pharmaceutical news, insider Deidre Greenway sold 12,980 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total transaction of $235,067.80. Following the completion of the transaction, the insider directly owned 40,049 shares in the company, valued at $725,287.39. This represents a 24.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Andrew Plump sold 116,191 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the sale, the insider owned 145,465 shares of the company's stock, valued at $2,689,647.85. This trade represents a 44.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 238,974 shares of company stock valued at $4,549,461. 0.04% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Provenance Wealth Advisors LLC bought a new stake in shares of Takeda Pharmaceutical during the third quarter worth approximately $27,000. Nisa Investment Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 28.8% during the third quarter. Nisa Investment Advisors LLC now owns 2,306 shares of the company's stock worth $42,000 after purchasing an additional 515 shares during the period. Bessemer Group Inc. lifted its stake in Takeda Pharmaceutical by 81.8% in the third quarter. Bessemer Group Inc. now owns 3,266 shares of the company's stock valued at $60,000 after buying an additional 1,470 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at approximately $59,000. Finally, Pinnacle Wealth Planning Services Inc. boosted its position in shares of Takeda Pharmaceutical by 9.9% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 7,881 shares of the company's stock worth $143,000 after purchasing an additional 711 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.